Product nameAnti-AIBZIP antibody [EPR7382]
See all AIBZIP primary antibodies
DescriptionRabbit monoclonal [EPR7382] to AIBZIP
Tested applicationsSuitable for: ICC, WBmore details
Unsuitable for: Flow Cyt,IHC-P or IP
Species reactivityReacts with: Human
Synthetic peptide within Human AIBZIP aa 250-350. The exact sequence is proprietary.
- Human prostate and breast cancer, PC3, LnCaP, MCF7, and T47D lysates.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at -20ºC.
Storage bufferPreservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab151736 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ICC||1/100 - 1/250.|
|WB||1/1000 - 1/10000. Predicted molecular weight: 43 kDa.|
FunctionTranscriptional activator that may play a role in the unfolded protein response. Binds to the UPR element (UPRE) but not to CRE element. Preferentially binds DNA with to the consensus sequence 5'-T[GT]ACGT[GA][GT]-3' and has transcriptional activation activity from UPRE. Binds to NF-kappa-B site and has transcriptional activation activity from NF-kappa-B-containing regulatory elements.
Tissue specificityAccording to PubMed:11830526, exclusively expressed in the prostate. Expressed in breast and prostate cancer cell lines. Expressed in prostatic luminal epithelial cells (at protein level). Expression is significantly more abundant in prostate cancer than in benign prostatic tissue (prostatic hyperplasia). According to PubMed:12111373, also expressed in brain, pancreas and skeletal muscle, and at lower levels in small intestine, testis, leukocyte and thymus.
Sequence similaritiesBelongs to the bZIP family. ATF subfamily.
Contains 1 bZIP domain.
modificationsN-glycosylated in the C-terminal region.
Controlled by regulated intramembrane proteolysis (RIP). Following ER stress a fragment containing the cytoplasmic transcription factor domain is released by proteolysis. The cleavage seems to be performed sequentially by site-1 and site-2 proteases (PS1 and PS2). PS1 cleavage may be suppressed by a determinant in the C-terminal region.
Cellular localizationNucleus. Under ER stress the cleaved N-terminal cytoplasmic domain translocates into the nucleus and Endoplasmic reticulum membrane. Golgi apparatus membrane. May also be located in Golgi apparatus.
- Information by UniProt
- 1700012K17Rik antibody
- AIbZIP antibody
- Androgen induced basic leucine zipper antibody
All lanes : Anti-AIBZIP antibody [EPR7382] (ab151736) at 1/1000 dilution
Lane 1 : Human prostate cancer lysate
Lane 2 : Human breast cancer lysate
Lane 3 : PC3 cell lysate
Lane 4 : LnCaP cell lysate
Lane 5 : MCF7 cell lysate
Lane 6 : T47D cell lysate
Lysates/proteins at 10 µg per lane.
All lanes : Goat anti-rabbit HRP at 1/2000 dilution
Predicted band size: 43 kDa
ab151736 has not yet been referenced specifically in any publications.